Hollywood stars sign open letter protesting the Paramount-Warner Bros. merger

More than 1,000 Hollywood professionals, including Bryan Cranston, Jane Fonda and Joaquin Phoenix, released an open letter opposing Paramount Skydance’s planned acquisition of Warner Bros. Discovery, warning it would reduce major U.S. film studios to four and worsen competition, jobs, and creative opportunities. The deal remains under active antitrust review in the U.S. and U.K., with California Attorney General Rob Bonta also saying it is not yet approved. The growing public and regulatory resistance increases execution risk for the transaction and could pressure sentiment around Paramount Skydance and Warner Bros. Discovery.

Analysis

The key market issue is not whether the deal is popular; it is whether the approval path becomes meaningfully longer and more expensive. For WBD, every incremental month of regulatory review raises the probability of financing friction, employee/customer churn, and a fallback toward a weaker standalone sale price if the process drags into 2H26. That asymmetry matters because media M&A lives or dies on timing: the longer the process, the more bargaining power shifts from the buyer to regulators, activists, and competing bidders.

The second-order effect is competitive, not just legal. If the transaction slows, WBD remains a structurally challenged asset with strategic optionality, while NFLX benefits from a weaker rival ecosystem and from any slowdown in legacy studio consolidation that could otherwise rationalize pricing power. The more probable medium-term loser is the broader linear-TV and cable-adjacent supply chain, where uncertainty suppresses programming commitments, ad-sales visibility, and production spend even before a final ruling.

The contrarian read is that this kind of public opposition can be a positive setup for the buyer if the market is already discounting regulatory risk too heavily; public campaigns often precede negotiated remedies rather than outright blockages. But the political overlay is now non-trivial: the combination of California, DOJ, and UK scrutiny increases the odds that approval, if it comes, is conditioned with remedies that reduce the synergy value. That means the base case is not a clean close, but a delayed, diluted transaction with asymmetric downside to WBD versus limited upside to NFLX from any failed deal.

Key Decisions for Investors

• Short WBD on rallies over the next 1-3 weeks; thesis is timeline extension and multiple compression if regulators signal a formal investigation. Risk/reward improves if the stock prices in a clean close that is now less likely.
• Consider a WBD put spread 3-6 months out to capture downside from regulatory delay while limiting premium burn if headlines stall; target a move toward pre-deal valuation bands rather than a binary collapse.
• Pair trade: long NFLX / short WBD for 2-4 months. If the merger drags, NFLX benefits from reduced consolidation pressure and less chance of a stronger integrated rival; the pair isolates deal-risk alpha rather than market beta.
• Avoid chasing WBD merger-arb exposure until there is clearer indication of remedy structure; the spread may look attractive, but the risk is a prolonged process that ties up capital with adverse carry.
• If WBD gaps lower on formal UK/US process milestones, cover part of the short into the first leg down and re-short on any reflex rally; the best entries are regulatory event-driven, not headline-driven.